Clinical Analysis of Thalidomide Companied Dexamethasone in the Treatment of Patients with Initial Multiple Myeloma_West China Medical Journal

Authors：

1Department of Hematology,the Central Hospital of Luoyang City, Luoyang Henan 471000;2 Department of Hematology,Sichuan Provincial People,s Hospital,Chengdu Sichuan 610072, China;

Corresponding?author：

Keywords：

沙利度胺; 地塞米松; 多發性骨髓瘤

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的:觀察沙利度胺聯合地塞米松(TD)治療初治多發性骨髓瘤(MM)的療效和毒副反應。方法:25例初治MM患者,給予沙利度胺(100mg/d起,每周增加50mg~100mg/d到200mg/d)聯合地塞米松40mg/d(d1~4,9~12,17~20),28天為一療程,至少2個療程。與既往18例使用VAD方案治療MM初治患者作對照。結果:觀察組25例中,14例部分緩解(56％),6例進步(24％),總有效率80%。對照組18例中,部分緩解13例,進步2例,總有效率83.3%。兩組總有效率無顯著性差異(P gt;0.05),但主要副作用發生率觀察組明顯少于對照組(P lt;0.05)。結論:沙利度胺聯合地塞米松(TD)治療多發性骨髓瘤療效高、副作用少和耐受性好,值得進一步的臨床觀察和推廣。老年患者(年齡 gt;65歲),地塞米松減量應用,可減少副作用,且不影響療效的發揮。

Citation： LI Bo,ZHANG JinLin,GAN Maozhou,et al.. Clinical Analysis of Thalidomide Companied Dexamethasone in the Treatment of Patients with Initial Multiple Myeloma. West China Medical Journal, 2009, 24(7): 1736-1739. doi: Copy

1.	RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
2.	BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
3.	RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
4.	張之南,主編.血液病診斷及療效標準[M]. 第2版.北京:科技出版社,1998:373-380.
5.	孫燕,周際昌,主編.臨床腫瘤內科手冊[M].第4版.北京:人民衛生出版社,2003:102-104.
6.	ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
7.	JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
8.	朱興虎,魏旭東,高全立,等.沙利度胺聯合地塞米松治療初發性多發性骨髓瘤的臨床觀察.白血病[J].淋巴瘤,2006,15(1):48-49.
9.	RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.

1. RICHARDSON P, SCHLOSSMAN R, JAGANNATH SRICHARDSON P, et al. Thalidomide for patients with relapse multiple myeloma after highdose chemotherapy and stem cell transplantation:results of an openlabel multicenter phase 2 studies of efficacy, toxicity, and biological activity [J]. Mayo Clin Proc, 2004, 79:875-882.
2. BERNARDESCHI P, DENTICO P, ROSSI S, et al. Chemoresistant myeloma:phase II clinical study with lowdose thalidomide plus highdose dexamethasone [J]. Chemother 2004, 16 (suppl 5):90-93.
3. RAJKUMAR S V, BLOOD E, VESOLE D, et al. Phase III trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma:a clinical trial coordinated by the Eastern Cooperative Oncology Group [J]. Clin Oncol, 2006, 24:431-436.
4. 張之南,主編.血液病診斷及療效標準[M]. 第2版.北京:科技出版社,1998:373-380.
5. 孫燕,周際昌,主編.臨床腫瘤內科手冊[M].第4版.北京:人民衛生出版社,2003:102-104.
6. ALEXANIAN R, DIMOPOULOS M A, DELASALLE K, et al. Primary dexamethasone treatment of multiple myeloma [J]. Blood, 1992, 80:887-890.
7. JIMENEZZEPEDA, DOMINGUEZMARTINEZ. Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? [J]. Eur J haematol, 2006, 77:239-244.
8. 朱興虎,魏旭東,高全立,等.沙利度胺聯合地塞米松治療初發性多發性骨髓瘤的臨床觀察.白血病[J].淋巴瘤,2006,15(1):48-49.
9. RAJKUMAR S V, JACOBUS S, CALLANDER N, et al. a randomized trial of lenaldomide plus highdose dexamethasone (rd) versus lenalidomide plus lowdose dexamethasone (RD) in newly diagnosed multiple myeloma (E4A03):a trial coordinated by the Eastern Cooperative Oncology Group[J].Blood,2007,110:31a.abstract 74.

West China Medical Journal

Clinical Analysis of Thalidomide Companied Dexamethasone in the Treatment of Patients with Initial Multiple Myeloma

Abstract Full text Figures/Tables Video References Cited by

Format

Content